RESUMEN
Many patients with Parkinson's disease (PD) experiencing l-DOPA-induced dyskinesia (LID) receive adjunct treatment with dopamine agonists, whose functional impact on LID is unknown. We set out to compare temporal and topographic profiles of abnormal involuntary movements (AIMs) after l-DOPA dose challenges including or not the dopamine agonist ropinirole. Twenty-five patients with PD and a history of dyskinesias were sequentially administered either l-DOPA alone (150% of usual morning dose) or an equipotent combination of l-DOPA and ropinirole in random order. Involuntary movements were assessed by two blinded raters prior and every 30 min after drug dosing using the Clinical Dyskinesia Rating Scale (CDRS). A sensor-recording smartphone was secured to the patients' abdomen during the test sessions. The two raters' CDRS scores were highly reliable and concordant with models of hyperkinesia presence and severity trained on accelerometer data. The dyskinesia time curves differed between treatments as the l-DOPA-ropinirole combination resulted in lower peak severity but longer duration of the AIMs compared with l-DOPA alone. At the peak of the AIMs curve (60-120 min), l-DOPA induced a significantly higher total hyperkinesia score, whereas in the end phase (240-270 min), both hyperkinesia and dystonia tended to be more severe after the l-DOPA-ropinirole combination (though reaching statistical significance only for the item, arm dystonia). Our results pave the way for the introduction of a combined l-DOPA-ropinirole challenge test in the early clinical evaluation of antidyskinetic treatments. Furthermore, we propose a machine-learning method to predict CDRS hyperkinesia severity using accelerometer data.
Asunto(s)
Discinesia Inducida por Medicamentos , Distonía , Enfermedad de Parkinson , Humanos , Antiparkinsonianos/efectos adversos , Agonistas de Dopamina/farmacología , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Hipercinesia , Levodopa/efectos adversos , Oxidopamina , Enfermedad de Parkinson/tratamiento farmacológicoRESUMEN
BACKGROUND: Coronavirus disease 2019 (COVID-19) is an infectious disease mainly affecting the respiratory system; however, a significant prevalence of neurological symptoms has been noted. OBJECTIVES: To investigate the incidence and characteristics of post-COVID-19 parkinsonism and to study dyskinesia related to COVID-19 vaccines. MATERIAL AND METHODS: The MEDLINE, PubMed, Scopus, and Web of Science databases were searched for all manuscripts relevant to post-COVID-19 parkinsonism and dyskinesia related to COVID-19 vaccines. Subsequently, we extracted and analysed data from the manuscripts in a structured manner. RESULTS: We found 24 patients with post-COVID-19 parkinsonism, with a mean onset age of 58 years after a mean of 30 days from the COVID-19 onset. Akinetic-rigid (n = 11) and mixed (n = 6) subtypes were the most common. Asymmetry was present in 13/15 patients. Brain MRI was unremarkable in 11/19, whereas dopaminergic system imaging was abnormal in 8/8 patients. Responsiveness to dopaminergic treatment was observed in 12/15 patients. Four patients improved after immunomodulatory therapy. Comorbidities were present in 9/24, encephalopathy symptoms in 11/24, and loss of smell in 9/13 patients. Most patients (n = 14) suffered serious COVID-19- related complications and three were treated with haloperidol. Parkinsonism improved (n = 5) or resolved (n = 4) during the follow-up. Five patients, with a mean age of 52, developed dyskinesia at a mean of 25 hours after receiving the COVID-19 mRNA vaccines. One patient had a history of neuropsychiatric symptoms and developed functional dyskinesia of the tongue. Four patients had a previous history of Parkinson's Disease (PD) with a mean duration of 10 years and developed dyskinesia and dystonia, which resolved (n = 2) or improved (n = 2) during the follow-up. CONCLUSIONS: Post-COVID-19 parkinsonism is a very rare complication, and it is likely that this is an umbrella syndrome that includes many different etiologies. Dyskinesia due to COVID-19 vaccines is exceedingly rare and probably has the same pathophysiological basis as in other conditions with exacerbation of PD symptoms.
Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Discinesia Inducida por Medicamentos , Trastornos Parkinsonianos , Humanos , Persona de Mediana Edad , COVID-19/complicaciones , Vacunas contra la COVID-19/efectos adversos , Dopamina , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/etiología , Incidencia , Trastornos Parkinsonianos/etiologíaRESUMEN
BACKGROUND: The prevalence of levodopa-induced dyskinesia (LID) in Parkinson's disease (PD) varies among geographical regions. Cultural differences in patient-based perceptions of LID have not been studied. OBJECTIVE: We compared patient and clinician evaluations of LID severity across multiple cultures in patients with PD. METHODS: The data set included the Unified Dyskinesia Rating (UDysRS) scores from 16 language translation programs (3566 patients). We defined the Perception Severity Index (PSI) as the ratio between normalized patient-based subjective ratings (UDysRS Part 1B) and normalized clinician examination (Parts 3 and 4) scores (Part 1B/Parts 3 + 4) and compared the PSI across languages. RESULTS: The mean PSI for the Chinese language (2.16) was higher than those of all other languages, whereas the ratio for the Korean language (0.73) was lower than those for Japanese, German, Turkish, Greek, Polish, and Finnish languages (corrected P values <0.05). CONCLUSIONS: Culture, as represented by language, affects the subjective perception of LID and needs to be considered in multinational clinical PD trials on dyskinesia. © 2023 International Parkinson and Movement Disorder Society.
Asunto(s)
Discinesia Inducida por Medicamentos , Enfermedad de Parkinson , Humanos , Enfermedad de Parkinson/complicaciones , Enfermedad de Parkinson/tratamiento farmacológico , Comparación Transcultural , Discinesia Inducida por Medicamentos/etiología , Discinesia Inducida por Medicamentos/diagnóstico , Levodopa/efectos adversos , AntiparkinsonianosRESUMEN
BACKGROUND AND HYPOTHESIS: There is a substantial gap in life expectancy between patients with severe mental illness (SMI) and the general population and it is important to understand which factors contribute to this difference. Research suggests an association between tardive dyskinesia (TD) and mortality; however, results are inconclusive. In addition, studies investigating associations between parkinsonism or akathisia and mortality are rare. We hypothesized that TD would be a risk factor for mortality in patients with SMI. STUDY DESIGN: We studied a cohort of 157 patients diagnosed predominantly with schizophrenia on the former Netherlands Antilles. TD, parkinsonism, and akathisia were assessed with rating scales on eight occasions over a period of 18 years. Twenty-four years after baseline, survival status and if applicable date of death were determined. Associations between movement disorders and survival were analyzed using Cox regression. Sex, age, antipsychotics, antidepressants and benzodiazepines at each measurement occasion were tested as covariates. STUDY RESULTS: Parkinsonism was a significant risk factor with an HR of 1.02 per point on the motor subscale of the Unified Parkinson's Disease Rating Scale (range 0-56). TD and akathisia were not significantly associated with mortality. CONCLUSIONS: Parkinsonism may be an important risk factor for mortality in SMI patients. This finding calls for more follow-up and intervention studies to confirm this finding and to explore whether treatment or prevention of parkinsonism can reduce excess mortality.
Asunto(s)
Antipsicóticos , Enfermedades de los Ganglios Basales , Discinesia Inducida por Medicamentos , Enfermos Mentales , Trastornos Parkinsonianos , Discinesia Tardía , Antipsicóticos/efectos adversos , Enfermedades de los Ganglios Basales/inducido químicamente , Enfermedades de los Ganglios Basales/diagnóstico , Enfermedades de los Ganglios Basales/epidemiología , Curazao , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/epidemiología , Discinesia Inducida por Medicamentos/etiología , Humanos , Agitación Psicomotora , Síndrome , Discinesia Tardía/inducido químicamenteRESUMEN
PURPOSE: The purpose of this article is to provide an overview of common adverse effects and management strategies related to atypical antipsychotic use. CONCLUSIONS: Atypical antipsychotics are commonly prescribed. While effective, atypical antipsychotics are associated with metabolic syndrome, extrapyramidal symptoms, and tardive dyskinesia, among others adverse effects. Management strategies can mitigate adverse effects and promote optimum quality of life. PRACTICE IMPLICATIONS: To be able to identify and manage adverse effects associated with the use of atypical antipsychotics, it is important to build a supportive therapeutic environment at each interaction with patients and their caregivers.
Asunto(s)
Antipsicóticos , Discinesia Inducida por Medicamentos , Antipsicóticos/efectos adversos , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Humanos , Calidad de VidaRESUMEN
Levodopa is the standard long-term dopamine replacement therapy to treat Parkinson's disease (PD) symptoms. With time, levodopa may induce debilitating dyskinesias (LID), the treatment of which represents a large clinically unmet need. However, time-to-LID onset varies between patients, reflecting a possible genetic component. We performed an hypothesis-free whole-exome sequencing (WES)-based screening of time-to-LID onset and attempted replication of previously published candidate gene studies. A WES association analysis was carried out in 134 PD patients in a meta-analytical framework. Replication was attempted in an independent study of 97 PD patients. Variants from previously reported candidate genes (OPRM1, COMT, BDNF) were also specifically examined. We significantly replicated, for the first time, an association of variant rs1799971 in the OPRM1 gene with time-to-LID onset. Furthermore, we identified two novel potentially functional variants, in the MAD2L2 (rs2233019) and MAP7 (rs35350783) genes, which were significantly associated at the discovery stage. In the replication study, the two variants showed direction-consistent effects but did not achieve the replication significance threshold. Our study provides the first WES results for time-to-LID onset, where we replicate association at OPRM1, and suggest new variants in MAD2L2 and MAP7 genes that are significant in discovery, but require larger datasets for replication. The results are being made publicly available to allow for independent external validation.
Asunto(s)
Susceptibilidad a Enfermedades , Discinesia Inducida por Medicamentos/etiología , Secuenciación del Exoma , Levodopa/efectos adversos , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/etiología , Anciano , Alelos , Biomarcadores , Discinesia Inducida por Medicamentos/diagnóstico , Femenino , Frecuencia de los Genes , Humanos , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Evaluación de SíntomasAsunto(s)
Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/genética , Modelos Genéticos , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/genética , Adulto , Edad de Inicio , Estudios de Cohortes , Femenino , Humanos , Levodopa/efectos adversos , Masculino , Persona de Mediana Edad , Análisis Multivariante , Enfermedad de Parkinson/tratamiento farmacológico , Valor Predictivo de las PruebasRESUMEN
Levodopa-induced dyskinesias are abnormal involuntary movements experienced by the majority of persons with Parkinson's disease (PwP) at some point over the course of the disease. Choreiform as the most common phenomenology of levodopa-induced dyskinesias can be managed by adjusting the dose/frequency of PD medication(s) based on a PwP's motor fluctuations over a typical day. We developed a sensor-based assessment system to provide such information. We used movement data collected from the upper and lower extremities of 15 PwPs along with a deep recurrent model to estimate dyskinesia severity as they perform different activities of daily living (ADL). Subjects performed a variety of ADLs during a 4-h period while their dyskinesia severity was rated by the movement disorder experts. The estimated dyskinesia severity scores from our model correlated highly with the expert-rated scores (r = 0.87 (p < 0.001)), which was higher than the performance of linear regression that is commonly used for dyskinesia estimation (r = 0.81 (p < 0.001)). Our model provided consistent performance at different ADLs with minimum r = 0.70 (during walking) to maximum r = 0.84 (drinking) in comparison to linear regression with r = 0.00 (walking) to r = 0.76 (cutting food). These findings suggest that when our model is applied to at-home sensor data, it can provide an accurate picture of changes of dyskinesia severity facilitating effective medication adjustments.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Discinesia Inducida por Medicamentos/diagnóstico , Levodopa/administración & dosificación , Enfermedad de Parkinson/tratamiento farmacológico , Dispositivos Electrónicos Vestibles , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Movimiento/efectos de los fármacosRESUMEN
Serotonergic medications are used for the prevention and treatment of depression during pregnancy. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors (SNRIs) can cause poor neonatal adaptation, which has been attributed to withdrawal versus toxicity. Bupropion, a norepinephrine-dopamine reuptake inhibitor, is often used as an adjunctive agent to selective serotonin reuptake inhibitors or SNRIs for refractory depression. Quetiapine, an atypical antipsychotic, may also be used in more complex cases. When combined with serotonergic drugs, bupropion and quetiapine are associated with increased risk of serotonin syndrome in adults. We describe a neonate exposed to venlafaxine (an SNRI), bupropion, and quetiapine in utero who presented nearly immediately after birth with encephalopathy and abnormal movements. The severity and rapidity of symptoms may be attributable to potentiation of venlafaxine's serotonergic effects by bupropion and quetiapine. Neonatal providers should be aware of maternal medications and prepare for possible adverse effects, particularly from common psychotropic exposures.
Asunto(s)
Antidepresivos/efectos adversos , Trastorno Bipolar/tratamiento farmacológico , Encefalopatías/inducido químicamente , Discinesia Inducida por Medicamentos/etiología , Inhibidores de la Captación de Neurotransmisores/efectos adversos , Complicaciones del Embarazo/tratamiento farmacológico , Trastornos por Estrés Postraumático/tratamiento farmacológico , Antidepresivos/uso terapéutico , Encefalopatías/congénito , Encefalopatías/diagnóstico , Bupropión/efectos adversos , Bupropión/uso terapéutico , Quimioterapia Combinada , Discinesia Inducida por Medicamentos/congénito , Discinesia Inducida por Medicamentos/diagnóstico , Femenino , Humanos , Recién Nacido , Masculino , Inhibidores de la Captación de Neurotransmisores/uso terapéutico , Embarazo , Fumarato de Quetiapina/efectos adversos , Fumarato de Quetiapina/uso terapéutico , Clorhidrato de Venlafaxina/efectos adversos , Clorhidrato de Venlafaxina/uso terapéuticoRESUMEN
We describe the case of a 12-year-old boy that developed invalidating motor symptoms after starting and gradually increasing the dose of quetiapine with extended release and phasing out aripiprazole. The symptoms met the definition of tardive dyskinesia given their duration and presentation. Symptoms decreased spontaneously after discontinuation of neuroleptic treatment. The literature and knowledge among clinicians concerning the occurrence of tardive dyskinesia in children and adolescents treated with atypical antipsychotics are limited. We give an overview of the available scientific findings with special attention to the presentation, the incidence and treatment possibilities.
Asunto(s)
Antipsicóticos , Discinesia Inducida por Medicamentos , Discinesia Tardía , Antipsicóticos/efectos adversos , Aripiprazol/efectos adversos , Niño , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/etiología , Humanos , Masculino , Fumarato de Quetiapina/efectos adversos , Discinesia Tardía/inducido químicamente , Discinesia Tardía/diagnósticoRESUMEN
A higher levodopa dose is a strong risk factor for levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). However, levodopa dose can change during long-term medication. We explored the relationship between levodopa dose and time to onset of LID using longitudinal multicenter data. Medical records of 150 patients who were diagnosed with de novo PD and treated with levodopa until onset of LID were collected. Levodopa dose were assessed as the dose at 6 months from levodopa initiation and rate of dose increase between 6 months and onset of LID. The groups with earlier LID onset had higher levodopa and levodopa-equivalent dose at the first 6 months of treatment and rapid increase in both levodopa and levodopa-equivalent dose. Multivariable linear regression models revealed that female sex, severe motor symptom at levodopa initiation, and higher rate of increase in both levodopa and levodopa-equivalent dose were significantly associated with early onset of LID. The present results demonstrated that rapid increase in levodopa dose or levodopa-equivalent dose is associated with early onset of LID.
Asunto(s)
Antiparkinsonianos/uso terapéutico , Discinesia Inducida por Medicamentos/diagnóstico , Levodopa/efectos adversos , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Antiparkinsonianos/efectos adversos , Relación Dosis-Respuesta a Droga , Discinesia Inducida por Medicamentos/etiología , Femenino , Humanos , Levodopa/uso terapéutico , Modelos Lineales , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/patología , Estudios Retrospectivos , Factores de Riesgo , Factores SexualesRESUMEN
INTRODUCTION: In patients with Parkinson's disease (PD), pulsatile dopaminergic stimulation may be a primary cause of levodopa-induced dyskinesia (LID). We aimed to investigate the correlation between levodopa pharmacokinetics (PK) and LID in PD. METHODS: We retrospectively reviewed the consecutive series of 255 PD patients without LID who underwent PK assessments with 100 mg levodopa. The type of peripheral decarboxylase inhibitor used in the PK assessments was determined by the usual prescription of the formulations of levodopa (10 mg carbidopa [n = 185] and 25 mg benserazide [n = 70]). RESULTS: During a median follow-up of 32 months (IQR, 16-49 months), 73 patients (29%) developed LID. Compared with patients who did not develop LID (PD-LID-), those who developed LID (PD-LID+) were younger (p = 0.003) and had significantly higher maximum levodopa concentration (Cmax) (p = 0.002) and area under the curve (p < 0.001), LEDD (p < 0.001), and improvement of motor symptoms (p = 0.009). In the multivariate Cox proportional hazards models, Cmax and AUC were associated with incident LID (Hazard Ratio [HR] 1.11, 95% confidence interval [CI] 1.03-1.19 and HR 1.13, 95% CI 1.03-1.24, respectively). In addition, younger age, benserazide use, LEDD, and MAOBI use were associated with incident LID. CONCLUSION: High levodopa plasma concentration after oral administration was associated with incident LID in patients with PD.
Asunto(s)
Dopaminérgicos/sangre , Discinesia Inducida por Medicamentos/diagnóstico , Levodopa/sangre , Enfermedad de Parkinson/tratamiento farmacológico , Anciano , Dopaminérgicos/administración & dosificación , Dopaminérgicos/efectos adversos , Discinesia Inducida por Medicamentos/etiología , Femenino , Estudios de Seguimiento , Humanos , Levodopa/administración & dosificación , Levodopa/efectos adversos , Masculino , Persona de Mediana Edad , Pronóstico , Estudios RetrospectivosRESUMEN
INTRODUCTION: Bupropion is the only Food and Drug Administration-approved synthetic cathinone. It increases the release of norepinephrine in the locus coeruleus and dorsal raphe nucleus, causing an increase in the frequency of serotonergic neuron firing. The diagnosis of serotonin toxicity (ST) from bupropion poisoning is controversial due to the lack of direct serotonergic activity. Nonetheless, there is one documented report of ST after single-agent bupropion overdose and multiple reports describing polypharmacy overdoses where bupropion may have contributed to ST. METHODS: This is a retrospective analysis of data collected by the Toxicology Investigators Consortium (ToxIC), a prospective multi-center toxico-surveillance and research network registry, from 2014 to 2017. Cases were identified if ST was a clinical effect and bupropion was the single agent listed. Data is presented descriptively. RESULTS: Of the 266 recorded single bupropion overdoses, the most common symptoms were seizures (47.1%), tachycardia (greater than 140 bpm) (33.9%), agitation (31.7%), toxic psychosis (20.4%), and myoclonus/tremor/hyperreflexia (19%). Benzodiazepines were the most common therapy (69.2%). Thirteen patients (5.9%) were diagnosed with ST by a medical toxicologist. CONCLUSION: Bupropion overdose is primarily associated with seizures, tachycardia, and agitation; bupropion may be an atypical cause of serotonin toxicity.
Asunto(s)
Antidepresivos de Segunda Generación/efectos adversos , Bupropión/efectos adversos , Síndrome de la Serotonina/inducido químicamente , Adolescente , Adulto , Cardiotoxicidad , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/epidemiología , Femenino , Humanos , Masculino , Prevalencia , Sistema de Registros , Estudios Retrospectivos , Convulsiones/inducido químicamente , Convulsiones/diagnóstico , Convulsiones/epidemiología , Síndrome de la Serotonina/diagnóstico , Síndrome de la Serotonina/epidemiología , Taquicardia/inducido químicamente , Taquicardia/diagnóstico , Taquicardia/epidemiología , Estados Unidos/epidemiología , Adulto JovenRESUMEN
Levodopa is widely used to treat Parkinson's disease (PD), and its long-term therapy may induce dyskinesia in a dose-dependent manner. However, the threshold dose with a relatively low risk for dyskinesia has not been determined. Demographic, clinical profiles and detailed information of dopaminergic drugs were recorded for 403 PD patients in treatment with levodopa. Variables were compared between dyskinesia and non-dyskinesia groups. Logistic regression analysis was used to assess the association between levodopa dose-related variables and dyskinesia. Receiver operating characteristic curve and decision tree classification model were used to investigate the cut-off value of levodopa dose to best separate the dyskinesia group from the non-dyskinesia group. Patients with dyskinesia tended to have a lower weight and age at onset, higher percentage of female and wearing-off, longer duration of disease and levodopa treatment, higher H-Y stage and MDS-UPDRS Part III score, and higher levodopa dose and levodopa equivalent dose than those without dyskinesia. After adjusted for demographical and clinical variables, levodopa dose-related factors (daily dose, cumulative dose, and weight-adjusted dose) were still associated with dyskinesia. Both the receiver operating characteristic and decision tree classification analysis indicated that patients who have taken levodopa dose ≤ 400 mg per day may be associated with a reduced risk for dyskinesia. In conclusion, we evaluated the thresholds of levodopa treatment with a relatively low risk for dyskinesia. These data should be considered for prevention and management of dyskinesia in patients with PD.
Asunto(s)
Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/efectos adversos , Discinesia Inducida por Medicamentos/epidemiología , Levodopa/administración & dosificación , Levodopa/efectos adversos , Enfermedad de Parkinson/epidemiología , China/epidemiología , Relación Dosis-Respuesta a Droga , Discinesia Inducida por Medicamentos/diagnóstico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Enfermedad de Parkinson/tratamiento farmacológico , Proyectos Piloto , Estudios Retrospectivos , Factores de RiesgoRESUMEN
A large and ever-growing number of medications can induce various movement disorders. Drug-induced movement disorders are disabling but are often under-recognised and inappropriately managed. In particular, second generation antipsychotics, like first generation agents, are associated with potentially debilitating side-effects, most notably tardive syndromes and parkinsonism, as well as potentially fatal acute syndromes. Appropriate, evidence-based management is essential as these drugs are being prescribed to a growing population vulnerable to these side-effects, including children and elderly people. Prevention of the development of drug-induced movement disorders is an important consideration when prescribing medications that can induce movement disorders. Recent developments in diagnosis, such as the use of dopamine transporter imaging for drug-induced parkinsonism, and treatment, with the approval of valbenazine and deutetrabenazine, the first drugs indicated for tardive syndromes, have improved outcomes for many patients with drug-induced movement disorders. Future research should focus on development of safer antipsychotics and specific therapies for the different tardive syndromes and the treatment of drug-induced parkinsonism.
Asunto(s)
Antipsicóticos/efectos adversos , Discinesia Inducida por Medicamentos/diagnóstico , Manejo de la Enfermedad , Discinesia Inducida por Medicamentos/prevención & control , Discinesia Inducida por Medicamentos/terapia , HumanosRESUMEN
BACKGROUND: Animal models of Parkinson's Disease (PD) demonstrated increased facilitatory cortico-striatal activity, reflecting overactive glutamatergic neurotransmission and contributing to the pathophysiology of l-dopa induced dyskinesias (LIDs). OBJECTIVE: To assess different facilitatory intracortical circuits in the primary motor cortex (M1) in patients with PD and LIDs by means of a combination of transcranial magnetic stimulation (TMS) protocols. METHODS: We tested the Input/Output (I/O) curve, intracortical facilitation (ICF) and short-interval intracortical facilitation (SICF) at baseline (T0), 'OFF' and 'ON' state, in 20 PD patients with LIDs. The same parameters were examined after 2 weeks of chronic intake of 50â¯mg (T1) and 100â¯mg/day (T2) of safinamide. Finally, we tested SICF in a further group of patients without LIDs. RESULTS: At T0, patients with LIDs showed increased I/O curve steepness, which was partly ameliorated by l-dopa. These patients also had normal ICF, and abnormally increased SICF, which did not change with l-dopa. Safinamide improved the I/O curve both at T1 and T2, it reduced SICF at T1 and normalized this measure at T2. In patients with PD and LIDs, SICF correlated with the severity of dyskinesia. In patients without LIDs, SICF was less prominently abnormal and responsive to l-dopa. CONCLUSIONS: Patients with PD and LIDs have abnormal cortical facilitation, possibly suggesting overactive glutamatergic neurotransmission in specific circuits within M1. Although not responsive to l-dopa, this dysfunction is restored by the anti-glutamatergic properties of safinamide 100â¯mg. The results suggest that the abnormal cortical facilitation in M1 contributes to the pathophysiology of LIDs.
Asunto(s)
Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/fisiopatología , Levodopa/efectos adversos , Enfermedad de Parkinson/diagnóstico , Enfermedad de Parkinson/fisiopatología , Estimulación Magnética Transcraneal/métodos , Anciano , Anciano de 80 o más Años , Alanina/análogos & derivados , Alanina/farmacología , Alanina/uso terapéutico , Animales , Bencilaminas/farmacología , Bencilaminas/uso terapéutico , Discinesia Inducida por Medicamentos/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Corteza Motora/efectos de los fármacos , Corteza Motora/fisiología , Enfermedad de Parkinson/tratamiento farmacológicoRESUMEN
In this review, we discuss respiratory dyskinesia, which is a rare adverse reaction to antipsychotic medications. The condition may mimic psychogenic hyperventilation syndrome or other respiratory or cardiac disorder. Respiratory dyskinesia is mostly seen in patients with tardive dyskinesia but may precede manifestations of tardive dyskinesia. If a patient receiving antipsychotic medication presents with symptoms of tachypnoea or acute respiratory distress, the possibility of respiratory dyskinesia should be considered, since it is a potentially reversible condition.
Asunto(s)
Antipsicóticos , Discinesia Inducida por Medicamentos , Antipsicóticos/efectos adversos , Discinesia Inducida por Medicamentos/diagnóstico , Discinesia Inducida por Medicamentos/terapia , Disnea , HumanosRESUMEN
This case report describes a patient, who presented with extrapyramidal side effects to the treatment with metoclopramide, which is used as an antiemetic, for gastroparesis and reflux. However, beyond its desired effect, serious neurological adverse reactions can be seen, which is why the European Medicines Agency and the Danish Medicines Agency have changed the recommendations for its use. If the extrapyramidal side effects include the respiratory muscles, the patient's ability to breathe can be affected. If a patient receiving metoclopramide or anti-psychotic drugs shows signs of tachypnoea or acute respiratory distress, the possibility of respiratory dyskinesia should always be considered.